Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2017

Open Access 01-12-2017 | Research article

Structural effects of intra-articular TGF-β1 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial

Authors: A. Guermazi, G. Kalsi, J. Niu, M. D. Crema, R. O. Copeland, A. Orlando, M. J. Noh, F. W. Roemer

Published in: BMC Musculoskeletal Disorders | Issue 1/2017

Login to get access

Abstract

Background

To determine effects of allogeneic human chondrocytes expressing TGF-β1 (TG-C) on structural progression of MRI features of knee osteoarthritis over a 1 year period.

Methods

This phase II randomized controlled trial of TG-C included patients with moderate to advanced osteoarthritis. Patients were randomized to receive an intraarticular 3:1 mixture of non-transduced allogeneic human chondrocytes and TG-C or placebo. 3 T MRI was acquired for all patients at baseline and follow-up (3, 6 and 12 months). MRIs were assessed using the WORMS system including cartilage damage, bone marrow lesions (BMLs), meniscal damage/extrusion, Hoffa-, effusion-synovitis, and osteophytes. Analyses were performed on a whole knee level, compartmental level, and subregional level. Binary logistic regression with Generalized Estimating Equation was used to compare risks of progression, adjusting for baseline age and gender. Mann − Whitney − Wilcoxon tests were used to assess differences for continuous variables.

Results

Fifty-seven Patients were included in the TG-C group and 29 in the placebo group. At 12 months, knees in the TG-C group showed less progression of cartilage damage compared to placebo on a whole knee level (34.6% vs. 47.9%; adjusted RR 0.7, 95%CI [0.5–1.1], p = 0.077). Less progression of Hoffa-synovitis and effusion-synovitis was observed in the TG-C group compared to placebo (9.6% vs. 21.1%, adjusted RR 0.5, 95%CI [0.2,1.2], p = 0.115). No statistically significant differences were seen for BMLs, meniscal damage and osteophytes.

Conclusions

Intraarticular treatment with TG-C showed fewer patients in the treated group with progression in structural OA features and other MRI-defined inflammatory markers such as Hoffa-synovitis and effusion-synovitis. However, no differences were observed in regard to progression of BMLs and meniscal damage, or hypertrophic osteophyte formation.

Trial registration

NCT01221441.Registered 13th October, 2010
Literature
1.
go back to reference MacFarlane EG, Haupt J, Dietz HC, Shore EM. TGF- β family signaling in connective tissue and skeletal diseases. Cold Spring Harb Perspect Biol. 2017. doi: 10.1101/cshperspect.a022269. [Epub ahead of print]. MacFarlane EG, Haupt J, Dietz HC, Shore EM. TGF- β family signaling in connective tissue and skeletal diseases. Cold Spring Harb Perspect Biol. 2017. doi: 10.​1101/​cshperspect.​a022269. [Epub ahead of print].
2.
go back to reference Lim CL, Lee YJ, Cho JH, Choi H, Lee B, Lee MC, et al. Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ. BMC Musculoskelet Disord. 2017;18:199.CrossRefPubMedPubMedCentral Lim CL, Lee YJ, Cho JH, Choi H, Lee B, Lee MC, et al. Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ. BMC Musculoskelet Disord. 2017;18:199.CrossRefPubMedPubMedCentral
3.
go back to reference Cherian JJ, Parvizi J, Bramlet D, Lee KH, Romness DW, Mont MA. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. Osteoarthr Cartil. 2015;23:2109–18.CrossRefPubMed Cherian JJ, Parvizi J, Bramlet D, Lee KH, Romness DW, Mont MA. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. Osteoarthr Cartil. 2015;23:2109–18.CrossRefPubMed
4.
go back to reference Cho JJ, Totterman S, Elmallah RK, Kim TW, Lee B, Mont MA. An MRI evaluation of patients who underwent treatment with a cell-mediated gene therapy for degenerative knee arthritis: a phase IIa clinical trial. J Knee Surg. 2016; doi: 10.1055/s-0036-1597275 [Epub ahead of print] [Epub ahead of print]. Cho JJ, Totterman S, Elmallah RK, Kim TW, Lee B, Mont MA. An MRI evaluation of patients who underwent treatment with a cell-mediated gene therapy for degenerative knee arthritis: a phase IIa clinical trial. J Knee Surg. 2016; doi: 10.​1055/​s-0036-1597275 [Epub ahead of print] [Epub ahead of print].
6.
go back to reference Peterfy CG, Guermazi A, Zaim S, Tirman PF, Miaux Y, White D, et al. Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis. Osteoarthr Cartil. 2004;12:177–90.CrossRefPubMed Peterfy CG, Guermazi A, Zaim S, Tirman PF, Miaux Y, White D, et al. Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis. Osteoarthr Cartil. 2004;12:177–90.CrossRefPubMed
7.
go back to reference Ha CW, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy. 2012;14:247.CrossRefPubMedPubMedCentral Ha CW, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy. 2012;14:247.CrossRefPubMedPubMedCentral
8.
go back to reference Ha CW, Cho JJ, Elmallah RK, Cherian JJ, Kim TW, Lee MC, et al. A multicenter, single-blind, phase IIa clinical trial to evaluate the efficacy and safety of a cell-mediated gene therapy in degenerative knee arthritis patients. Hum Gene Ther Clin Dev. 2015;26:125–30.CrossRefPubMed Ha CW, Cho JJ, Elmallah RK, Cherian JJ, Kim TW, Lee MC, et al. A multicenter, single-blind, phase IIa clinical trial to evaluate the efficacy and safety of a cell-mediated gene therapy in degenerative knee arthritis patients. Hum Gene Ther Clin Dev. 2015;26:125–30.CrossRefPubMed
9.
go back to reference Lee MC, Ha CW, Elmallah RK, Cherian JJ, Cho JJ, Kim TW, et al. A placebo-controlled randomized trial to assess the effect of TGF-β1-expressing chondrocytes in patients with arthritis of the knee. Bone Joint J. 2015;97-B(7):924–32.CrossRefPubMed Lee MC, Ha CW, Elmallah RK, Cherian JJ, Cho JJ, Kim TW, et al. A placebo-controlled randomized trial to assess the effect of TGF-β1-expressing chondrocytes in patients with arthritis of the knee. Bone Joint J. 2015;97-B(7):924–32.CrossRefPubMed
10.
go back to reference Alizai H, Roemer FW, Hayashi D, Crema MD, Felson DT, Guermazi A. An update on risk factors for cartilage loss in knee osteoarthritis assessed using MRI-based semiquantitative grading methods. Eur Radiol. 2015;25:883–93.CrossRefPubMed Alizai H, Roemer FW, Hayashi D, Crema MD, Felson DT, Guermazi A. An update on risk factors for cartilage loss in knee osteoarthritis assessed using MRI-based semiquantitative grading methods. Eur Radiol. 2015;25:883–93.CrossRefPubMed
11.
go back to reference Hayashi D, Roemer FW, Guermazi A. Imaging for osteoarthritis. Ann Phys Rehabil Med. 2016;59:161–9.CrossRefPubMed Hayashi D, Roemer FW, Guermazi A. Imaging for osteoarthritis. Ann Phys Rehabil Med. 2016;59:161–9.CrossRefPubMed
12.
go back to reference Noh MJ, Copeland RO, Yi Y, Choi KB, Meschter C, Hwang S, et al. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). Cytotherapy. 2010;12:384.CrossRefPubMed Noh MJ, Copeland RO, Yi Y, Choi KB, Meschter C, Hwang S, et al. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). Cytotherapy. 2010;12:384.CrossRefPubMed
Metadata
Title
Structural effects of intra-articular TGF-β1 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial
Authors
A. Guermazi
G. Kalsi
J. Niu
M. D. Crema
R. O. Copeland
A. Orlando
M. J. Noh
F. W. Roemer
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2017
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-017-1830-8

Other articles of this Issue 1/2017

BMC Musculoskeletal Disorders 1/2017 Go to the issue